84 related articles for article (PubMed ID: 38656242)
1. Severity of COVID-19 in patients with lung cancer: evidence and challenges.
Passaro A; Bestvina C; Velez Velez M; Garassino MC; Garon E; Peters S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737345
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
3. Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer.
Peng S; Huang H; Chen J; Ding X; Zhu X; Liu Y; Chen L; Lu Z
Technol Cancer Res Treat; 2024; 23():15330338241248573. PubMed ID: 38656242
[No Abstract] [Full Text] [Related]
4. Impact of severe-to-very severe chronic obstructive pulmonary disease on the prognosis of patients with non-small cell lung cancer who received chemotherapy.
Dong W; Zhu Y; Du Y; Wang L; Feng X; Ma S
Clin Respir J; 2020 Apr; 14(4):345-352. PubMed ID: 31876095
[TBL] [Abstract][Full Text] [Related]
5. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Garassino MC; Whisenant JG; Huang LC; Trama A; Torri V; Agustoni F; Baena J; Banna G; Berardi R; Bettini AC; Bria E; Brighenti M; Cadranel J; De Toma A; Chini C; Cortellini A; Felip E; Finocchiaro G; Garrido P; Genova C; Giusti R; Gregorc V; Grossi F; Grosso F; Intagliata S; La Verde N; Liu SV; Mazieres J; Mercadante E; Michielin O; Minuti G; Moro-Sibilot D; Pasello G; Passaro A; Scotti V; Solli P; Stroppa E; Tiseo M; Viscardi G; Voltolini L; Wu YL; Zai S; Pancaldi V; Dingemans AM; Van Meerbeeck J; Barlesi F; Wakelee H; Peters S; Horn L;
Lancet Oncol; 2020 Jul; 21(7):914-922. PubMed ID: 32539942
[TBL] [Abstract][Full Text] [Related]
7. Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls.
DeBolt CA; Bianco A; Limaye MA; Silverstein J; Penfield CA; Roman AS; Rosenberg HM; Ferrara L; Lambert C; Khoury R; Bernstein PS; Burd J; Berghella V; Kaplowitz E; Overbey JR; Stone J
Am J Obstet Gynecol; 2021 May; 224(5):510.e1-510.e12. PubMed ID: 33221292
[TBL] [Abstract][Full Text] [Related]
8. Characteristics in Pediatric Patients with Coronavirus Disease 2019 in Korea.
Seon JY; Jeon WH; Bae SC; Eun BL; Choung JT; Oh IH
J Korean Med Sci; 2021 May; 36(20):e148. PubMed ID: 34032033
[TBL] [Abstract][Full Text] [Related]
9. Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination.
Peng H; Xiang T; Xu F; Jiang Y; Zhong L; Peng Y; Le A; Zhang W; Liu Y
Microorganisms; 2023 Apr; 11(4):. PubMed ID: 37110363
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC.
Huang H; Zhong P; Zhu X; Fu S; Li S; Peng S; Liu Y; Lu Z; Chen L
Front Oncol; 2023; 13():1137224. PubMed ID: 37035161
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.
Zhang L; You Y; Liu X; Liu F; Nie K; Ji Y
Thorac Cancer; 2023 May; 14(15):1355-1361. PubMed ID: 37016906
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.
Fu S; Huang H; Shang K; Tu G; Zhong P; Li S; Zhu X; Peng S; Liu Y; Lu Z; Chen L
Future Oncol; 2023 Jan; 19(2):147-158. PubMed ID: 36779488
[TBL] [Abstract][Full Text] [Related]
13. As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?
Xu R; Wang W; Zhang W
Front Public Health; 2022; 10():1039123. PubMed ID: 36504951
[TBL] [Abstract][Full Text] [Related]
14. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer.
Maki M; Takada R; Taniguchi A; Nomura N; Kuramoto S; Chiko Y; Okada T; Saito S; Tamura K
J Pharm Health Care Sci; 2022 Nov; 8(1):27. PubMed ID: 36316726
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
